|
Title
|
|
|
|
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Cell. - Cambridge, Mass.
| |
|
Publication
|
|
|
|
Cambridge, Mass.
:
2010
| |
|
ISSN
|
|
|
|
0092-8674
| |
|
DOI
|
|
|
|
10.1016/J.CELL.2010.02.039
| |
|
Volume/pages
|
|
|
|
141
:1
(2010)
, p. 178-190
| |
|
ISI
|
|
|
|
000276211100022
| |
|
Pubmed ID
|
|
|
|
20371353
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|